Trophos Completes Patient Enrolment In Olesoxime Phase 3 Trial
The Phase 3 study is an 18-month randomised, parallel group, double-blind, placebo controlled trial evaluating the efficacy and safety of Olesoxime against placebo in patients diagnosed with ALS
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.